Skip to content
SENSEERA logo — Empowering diagnostics and drug development with AI-driven c...

SENSEERA

Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy

Founded 2020 Israel Israel 20 employees Health Care

General Information

Company Name SENSEERA
Founded Year 2020
Location Israel Israel
Employees 20
Industries Health Care
Business Model B2B, DaaS, Platform
Revenue Model Service Fee, Data Monetization, Project Based
Social

BounceWatch is an independent company data service, not affiliated with SENSEERA. To contact SENSEERA, visit senseerahealth.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SENSEERA compare?

A PDF of SENSEERA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SENSEERA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SENSEERA

SENSEERA is a promising player in the Health Care sector, founded in 2020 and based in Israel. The company is pioneering advancements in diagnostics and drug development with its AI-driven chromatin liquid biopsy technology.

The foundation of SENSEERA's innovation is its patented GEM (Genomic Expression Maps) Biomarkers, which transform a simple blood draw into intricate, quantitative data about gene expression and regulation. This platform allows for more precise biomarker discovery, early and tissue-agnostic MRD detection, therapy response monitoring, and disease subtyping, significantly outperforming traditional methods.

With a rapidly growing database of over 20,000 disease samples and a collaboration network including leading pharmaceutical and biotech companies, SENSEERA provides critical mechanistic insights. Their technology ensures high sensitivity and specificity, crucial for advancing precision medicine and accelerating drug development worldwide.

Business keywords: AI-driven diagnostics, chromatin liquid biopsy, biomarker discovery, Genomic Expression Maps, cell-free DNA analysis, tissue-agnostic MRD detection, therapy response monitoring, dose optimization, disease subtyping, precision medicine, drug development collaboration, quantitative gene expression, regulatory data, sensitivity and specificity, biotech partnerships

Services & Products

AI-driven chromatin liquid biopsy
Diagnostic platform for disease monitoring
Non-invasive gene expression analysis
Biomarker generation for treatment monitoring

Target Customers

Pharmaceutical companies Biotechnology firms Clinical researchers Healthcare providers Diagnostic laboratories

No funding data available for SENSEERA yet.

SENSEERA Alternatives & Competitors

View All Alternatives
SENSEERA vs
Predicine
Predicine United States

Advancing precision medicine through next-generation liquid biopsy oncology platform

89 employees
Biotechnology, Health Care
SENSEERA vs

Discovering the future of diagnostics with unparalleled accuracy.

Seed
6 employees
Biotechnology, Health Care
SENSEERA vs
Capio Biosciences
Capio Biosciences United States

Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information...

Series A
4 employees
Biotechnology, Health Care

FAQ About SENSEERA

Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy
SENSEERA was founded in 2020.
SENSEERA is headquartered in Israel.
SENSEERA operates in Health Care. Its work centres on AI-driven diagnostics, chromatin liquid biopsy, biomarker discovery and Genomic Expression Maps. Its customers include Pharmaceutical companies, Biotechnology firms and Clinical researchers.
SENSEERA has a B2B, DaaS and Platform business model. Its revenue comes from Service Fee, Data Monetization and Project Based.
SENSEERA has approximately 20 employees.
SENSEERA offers: AI-driven chromatin liquid biopsy, Diagnostic platform for disease monitoring, Non-invasive gene expression analysis, Biomarker generation for treatment monitoring.
Top alternatives and competitors to SENSEERA include Predicine, Paradise Genomics, Inc., Capio Biosciences, NVIGEN Inc., HaploX Global. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SENSEERA and Predicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SENSEERA, https://bouncewatch.com/company/senseera, updated 5 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout